Invokana canagliflozin: Additional Phase III data - BioCentury.comHome > Week in Review > Clinical Results > Invokana canagliflozin: Additional Phase III dataInvokana canagliflozin: Additional Phase III dataMitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, JapanJohnson & Johnson (NYSE:JNJ), New Brunswick, N.J.OrganizationsJohnson & JohnsonMitsubishi Tanabe Pharma Corp.ProductsInvokanaJNJ-28431754TA-7284Molecular TargetsSodium-glucose cotransporter 2 (SGLT2)
